000 01521 a2200457 4500
005 20250515144203.0
264 0 _c20090430
008 200904s 0 0 eng d
022 _a1745-7254
024 7 _a10.1111/j.1745-7254.2008.00865.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHu, Bi
245 0 0 _aBioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin.
_h[electronic resource]
260 _bActa pharmacologica Sinica
_cNov 2008
300 _a1357-69 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAngiogenesis Inhibitors
_ximmunology
650 0 4 _aAnimals
650 0 4 _aAntineoplastic Agents
_ximmunology
650 0 4 _aEndostatins
_ximmunology
650 0 4 _aEndothelial Cells
_xdrug effects
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMacaca mulatta
650 0 4 _aMale
650 0 4 _aMice
650 0 4 _aRecombinant Proteins
_ximmunology
650 0 4 _aSex Characteristics
650 0 4 _aTetrazolium Salts
650 0 4 _aThiazoles
700 1 _aZhu, Hao-wen
700 1 _aZhu, Li-ping
700 1 _aLi, Chen
700 1 _aRong, Zhi-gang
700 1 _aXu, Jia-ming
700 1 _aWu, Zhi-wei
700 1 _aWang, Jian-jun
700 1 _aXu, Gen-xing
773 0 _tActa pharmacologica Sinica
_gvol. 29
_gno. 11
_gp. 1357-69
856 4 0 _uhttps://doi.org/10.1111/j.1745-7254.2008.00865.x
_zAvailable from publisher's website
999 _c18416957
_d18416957